Hillgene Biopharma won the "2022 China Biomedicine Industry Chain Innovation Ranking" the most concerned new enterprises Golden Horse Award

On December 30, 2022, the "2022 China Biopharmaceutical Industry Innovation Excellence List" was officially announced at the opening ceremony of the "Second China Biopharmaceutical Industry Chain Innovation and Transformation Summit." Jiangsu Hillgene Biopharmaceutical Co., Ltd. successfully secured the "Gold Horse Award" and was recognized as the "Most Watched Emerging Enterprise of 2022."

This list was compiled using data from various sources, including the New Drug Research and Development Monitoring Database, Comprehensive Drug Database, and Drug Migration Database. Guided by the national "Major New Drug Creation" special project, the evaluation criteria were established across 12 dimensions, such as novel drug targets, technological advancements, clinical needs, and research and development investments. A panel of academicians and experts conducted video conferences, online voting, and weighted comprehensive assessments to select the benchmark awards, the Kunpeng Awards, and the Gold Horse Awards. This list has become a prominent award in the field of innovation and transformation in the biopharmaceutical industry.

As the first company in the country to be granted the "Drug Production Permit" for the full-process entrusted production of CAR-T cell therapy drugs, Hillgene Biopharma is dedicated to providing its customers with comprehensive, quality-assured, and three-dimensional full-process Cell and Gene Therapy Contract Development and Manufacturing Organization (CQDMO) services.

This award not only signifies the attention garnered by Hillgene Biopharma's innovative advancements but also serves as an inspiration for further breakthroughs in the CQDMO field. In the future, Hillgene Biopharma will continue to aim at setting industry standards, optimizing service models, accelerating the development of cell therapy drugs, and pushing more of these innovative therapies into the market.

Post time: 2023-02-17 00:00:00